KPTI vs. MLTX
KPTI (Karyopharm Therapeutics Inc.) and MLTX (MoonLake Immunotherapeutics) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, KPTI returned -43.70%/yr vs 12.25%/yr for MLTX. At a 0.14 correlation, their price movements are largely independent.
Performance
KPTI vs. MLTX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KPTI achieves a 15.49% return, which is significantly lower than MLTX's 36.57% return.
KPTI
- 1D
- -6.39%
- 1M
- -1.62%
- YTD
- 15.49%
- 6M
- 44.31%
- 1Y
- 89.31%
- 3Y*
- -36.47%
- 5Y*
- -43.70%
- 10Y*
- -23.75%
MLTX
- 1D
- 0.56%
- 1M
- 5.51%
- YTD
- 36.57%
- 6M
- 19.44%
- 1Y
- -61.60%
- 3Y*
- -14.95%
- 5Y*
- 12.25%
- 10Y*
- —
KPTI vs. MLTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
KPTI Karyopharm Therapeutics Inc. | 15.49% | -27.45% | -21.82% | -74.56% | -47.12% | -58.46% | 4.67% |
MLTX MoonLake Immunotherapeutics | 36.57% | -75.66% | -10.33% | 475.14% | 6.17% | -13.02% | 8.39% |
Correlation
The correlation between KPTI and MLTX is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.12 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.15 |
Correlation (All Time) Calculated using the full available price history since Oct 21, 2020 | 0.14 |
Fundamentals
KPTI:
$210.08M
MLTX:
$1.28B
KPTI:
-$13.00
MLTX:
-$3.90
KPTI:
$151.12M
MLTX:
$0.00
KPTI:
$145.13M
MLTX:
-$1.49M
KPTI:
-$93.05M
MLTX:
-$179.84M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KPTI vs. MLTX — Risk / Return Rank
KPTI
MLTX
KPTI vs. MLTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Karyopharm Therapeutics Inc. (KPTI) and MoonLake Immunotherapeutics (MLTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| KPTI | MLTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.49 | ||
| Sortino ratioReturn per unit of downside risk | +1.25 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.18 | +0.05 |
| Calmar ratioReturn relative to maximum drawdown | 1.86 | -0.69 | +2.54 |
| Martin ratioReturn relative to average drawdown | 4.59 | -0.98 | +5.56 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| KPTI | MLTX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.95 | -0.53 | +1.49 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.46 | 0.14 | -0.60 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.28 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.27 | 0.12 | -0.38 |
Drawdowns
KPTI vs. MLTX - Drawdown Comparison
The maximum KPTI drawdown since its inception was -99.50%, which is greater than MLTX's maximum drawdown of -90.22%. Use the drawdown chart below to compare losses from any high point for KPTI and MLTX.
Loading charts...
Drawdown Indicators
| KPTI | MLTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.50% | -90.22% | -9.28% |
Max Drawdown (1Y)Largest decline over 1 year | -48.36% | -89.93% | +41.57% |
Max Drawdown (3Y)Largest decline over 3 years | -89.32% | -90.22% | +0.90% |
Max Drawdown (5Y)Largest decline over 5 years | -98.36% | -90.22% | -8.14% |
Max Drawdown (10Y)Largest decline over 10 years | -99.15% | — | — |
Current DrawdownCurrent decline from peak | -98.80% | -71.81% | -26.99% |
Average DrawdownAverage peak-to-trough decline | -75.28% | -29.24% | -46.04% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.53% | 63.21% | -43.68% |
Volatility
KPTI vs. MLTX - Volatility Comparison
Karyopharm Therapeutics Inc. (KPTI) has a higher volatility of 24.86% compared to MoonLake Immunotherapeutics (MLTX) at 18.65%. This indicates that KPTI's price experiences larger fluctuations and is considered to be riskier than MLTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KPTI | MLTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 24.86% | 18.65% | +6.21% |
Volatility (6M)Calculated over the trailing 6-month period | 62.32% | 55.24% | +7.08% |
Volatility (1Y)Calculated over the trailing 1-year period | 94.32% | 115.84% | -21.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 94.91% | 91.15% | +3.76% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 86.51% | 86.45% | +0.06% |
Dividends
KPTI vs. MLTX - Dividend Comparison
Neither KPTI nor MLTX has paid dividends to shareholders.
Financials
KPTI vs. MLTX - Financials Comparison
This section allows you to compare key financial metrics between Karyopharm Therapeutics Inc. and MoonLake Immunotherapeutics. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
KPTI and MLTX have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
KPTI has higher volatility (24.86%) compared to MLTX (18.65%). In terms of maximum drawdown, KPTI dropped -99.50% vs MLTX's -90.22%.
KPTI currently has the higher Sharpe Ratio (0.95 vs -0.53), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KPTI and MLTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer